ADA: Once-Weekly Tirzepatide Yields Lasting Weight Loss in Obesity

TUESDAY, June 7, 2022 (HealthDay News) -- For individuals with obesity, tirzepatide is associated with lasting weight loss, according to a study published online June 4 in the New England Journal of Medicine to coincide with the annual meeting of the American Diabetes Association, held from June 3 to 7 in New Orleans.
Ania M. Jastreboff, M.D., Ph.D., from the Yale University School of Medicine in New Haven, Connecticut, and colleagues conducted a phase 3 trial involving 2,539 adults with a body mass index of 30 kg/m² or more or 27 kg/m² or more and at least one weight-related complication, excluding diabetes. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5, 10, or 15 mg) or placebo for 72 weeks in a 1:1:1:1 ratio.
The researchers found that the mean percentage change in weight was −15.0, −19.5, and −20.9 percent for the 5-, 10-, and 15-mg weekly doses of tirzepatide, respectively, and −3.1 percent with placebo. The percentages of participants with a weight reduction of 5 percent or more were 85, 89, and 91 percent for the 5-, 10-, and 15-mg weekly doses of tirzepatide, respectively, and 35 percent with placebo; a reduction in body weight of 20 percent or more occurred in 50 and 57 percent of participants in the 10- and 15-mg tirzepatide groups, respectively, and in 3 percent of those in the placebo group. In all prespecified cardiometabolic measures, there were improvements observed with tirzepatide.
"Obesity should be treated like any other chronic disease -- with effective and safe approaches that target underlying disease mechanisms, and these results underscore that tirzepatide may be doing just that," Jastreboff said in a statement.
Several authors disclosed financial ties to biopharmaceutical companies, including Eli Lilly, which manufactures tirzepatide and funded the study.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Related Posts
Cancer Survivors Face Transportation Barriers to Accessing Care
WEDNESDAY, March 30, 2022 (HealthDay News) -- Cancer survivors are more likely...
¿Las inyecciones de cortisona son buenas o malas para las rodillas con artritis?
MARTES, 21 de diciembre de 2021 (HealthDay News) -- Las inyecciones de cortisona...
EU Drug Regulator Approves Pfizer COVID-19 Vaccine Booster Shots
MONDAY, Oct. 4, 2021 (HealthDay News) -- Booster shots of the Pfizer-BioNTech...
New U.S. Monkeypox Coordinator Named
TUESDAY, Aug. 2, 2022 (HealthDay News) -- The White House announced Tuesday...